Stockreport

Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62n? Annual ESPE Meeting 2024

Lumos Pharma, Inc.  (LUMO) 
PDF AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, anno [Read more]